Как гибнут великие и почему некоторые компании никогда не сдаются

10, no. 6 (November/December 2004): 551—554: Claire Bombardier. Loren Laine, Alise Reicin. et al. for the VIGOR Study Group. “Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients With Rheumatoid Arthritis." New England Journal of Medicine 343, no. 21 (November 23. 2000): 1520—1528. http://content.nej m.org/cgi/content/full/ 343/21/1520.

62. Peter S. Kim and Alise S. Reicin. “Refecoxib, Merck and the FDA." New England Journal of Medicine 351. no. 27 (December 30, 2004): 28 75—28 78; John Simons and David Stipp, “Will Merck Survive Yioxx?" Fortune, November 1. 2004, 90.

63. Merck & Co., Inc., Annual Report 2002 (Whitehouse Station. NJ: Merck & Co., Inc., 2003); Merck & Co.. Inc., Annual Report 2004 (Whitehouse Station, NJ: Merck & Co., Inc., 2005); Susan Dentzer. “Drug Failure." Online NewsHour, November 18, 2004, http://www.pbs.oi)£/ newshour/bb/health/j u ly-dec04/vioxx n-i&html.

64. Eric J. Topol, “Failing the Public Health — Rofecoxib, Merck, and the FDA," New England Journal of Medicine 351, no. 17 (October 21.

2004): 1701 — 1709; Debabrata Mukheijee, Steven E. Nissen, and Eric J. Topol, “Risk of Cardiovascular Events Associated with Selective COX-2 Inhibitors,” Journal of the American Medical Association 286, no. 8 (August 22, 2001): 954—959; Daniel H. Solomon, Sebastian Schneeweiss, Robert J. Glynn, et al., “Relationship Between Selective Cyclooxygenase-2 Inhibitors and Acute Myocardial Infarction in Older Adults," Circulation 109 (April 19, 2004): 2068—2073, http://circ.ahajoumals.org/cgi/content /full/109/17/2068.

65. Peter S. Kim and Alise S. Reicin, “Rofecoxib, Merck and the FDA," New England Journal of Medicine 351, no. 27 (December 30, 2004): 2875-2878.

66. Merck & Co., Inc., Annual Report 2004 (Whitehouse Station, NJ: Merck & Co., Inc., 2005), 21.

67. Brooke A. Masters and Marc Kaufman, “Painful Withdrawal for Makers of Yioxx,” Washington Post, October 18, 2004.

68. Christopher Rowland, “CEO Defends Merck on Vioxx: Confirmation of Woes Came ‘Out of Blue,'" Boston Globe, October 9, 2004, http://www.boston.com/business/articles/2GQ4/lo/Q9/ceo_defends_ merck_on_vioxx; Merck & Co., Inc. “Company Statements," VIOXX® (rofecoxib)InformationCenter,http//www.merck.com/newsroom/ vioxx/archive.html#company_statements.

69. John Simons and David Stipp, “Will Merck Survive Vioxx?” Fortune, November 1, 2004, 90.

70. George W. Merck, “Talk by George W. Merck at the Medical College of Virginia at Richmond," December 1, 1950.

71. Jim Collins, Good to Great: Why Some Companies Make the Leap ... And Others Don’t (New York: HarperCollins, 2001). 22. G. Christian Hill and Mike Tharp, “Stumbling Giant," Wall Street Journal, July 18, 1985.

73. Garrett G. Fagan, Emperors of Rome (Chantilly, VA: The Teaching Company Limited Partnership, 2007), audiotapes of lectures by Garrett G. Fagan, Lectures 3—6,10. тр. 73

Стадия 3: отрицание риска и опасности

74. Ed Viesturs and David Roberts, No Shortcuts to the Top (New York: The Doubleday Broadway Publishing Group, 2006), 158.

75. Jill Bettner, ’“Underpromise, Overperform,"’ Forbes, January 30,

1984, 88; Motorola, Inc., “Note 2 to Consolidated Financial State-

ments," 1996 Summary Annual Report (Schaumburg, IL: Motorola, Inc., 1997).

76. Sydney Finkelstein and Shade H. Sanford, “Learning from Corporate Mistakes: The Rise and Fall of Iridium," Organizational Dynamics 29, no. 2 (November 2000): 138—148.

77. Sydney Finkelstein and Shade H. Sanford, “Learning from Corporate Mistakes: The Rise and Fall of Iridium," Organizational Dynamics 29, no. 2 (November 2000): 138—148.

78. Rajiv Chandrasekaran, “Motorola’s Next Page: The Cellular Giant and Onetime Stock Star Seeks Ways to Renew Its Growth,” Washington Fost, September 29, 1996.

79. Motorola, Inc., “Letter to Stockholders,” 1997 Summary Annual Report (Schaumburg, IL: Motorola, Inc., 1998), 6.

80. Sydney Finkelstein and Shade H. Sanford, “Learning from Corporate Mistakes: The Rise and Fall of Iridium ” Organizational Dynamics 29, no. 2 (November 2000): 138—148.

81. Motorola, Inc., 1999 Proxy Statement (Schaumburg. IL: Motorola, Inc., 2000), httpy/mediaxorporate-irjiet/media.files/ irol/9o/9o829/proxies /mot.000324.1999_proxyhtm.

82. Caleb Pirtle III, Engineering the World: Stories from the First 75 Years of Texas Instruments (Dallas: Southern Methodist University Press,

2005), 153; Joan Terrall, “Texas Instruments, Incorporated: 1983,” Harvard Business School, case study #9-184-109 (Boston: Harvard Business School Publishing, 1984), 10.

83. Robert Ristelhueber, “Texas Tornado," Electronic Business 23. no. 12 (December 1997): 35.